If Biotech Cannot Make Enough Money from Curing Disease Then Move on to Antiaging

Goldman Sachs analysts asked "Is curing patients a sustainable business model?" analysts ask in an April 10 report entitled "The Genome Revolution." Goldman was addressing the...

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]